Onyx Pharmaceuticals To Present At BIO Investor Forum
EMERYVILLE, CALIF. Oct. 17, 2005
Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including sorafenib with Bayer Pharmaceuticals Corporation. For more information about Onyx’s pipeline and activities, visit the company’s website at www.onyx‑pharm.com.
Back to 2005 Press Releases